5-Alpha-Reductase Inhibitors and Combination Therapy

被引：17

作者：

Fuellhase, Claudius ^{[1
]}

Schneider, Marc P. ^{[2
]}

机构：

[1] Univ Rostock, Dept Urol, Ernst Heydemann Str 6, D-18057 Rostock, Germany

[2] Univ Zurich, Brain Res Inst, Swiss Fed Inst Technol Zurich, Dept Hlth Sci & Technol, Winterthurerstr 190, CH-8057 Zurich, Switzerland

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2016年 / 43卷 / 03期

关键词：

5-Alpha-reductase inhibitors; Finasteride; Dutasteride; Combination drug therapy; Prostatic hyperplasia; Lower urinary tract symptoms; BENIGN PROSTATIC HYPERPLASIA; URINARY-TRACT SYMPTOMS; DOUBLE-BLIND; FINASTERIDE THERAPY; TRANSURETHRAL RESECTION; ENLARGED PROSTATE; 5A-REDUCTASE INHIBITORS; CLINICAL PROGRESSION; SEXUAL FUNCTION; BLOOD-LOSS;

D O I：

10.1016/j.ucl.2016.04.003

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

By inhibiting the conversion from testosterone to dihydrotestosterone 5-Alpha reductase inhibitors (5ARIs) are able to hinder prostatic growth, shrink prostate volumes, and improve BPH-related LUTS. 5ARIs are particularly beneficial for patients with larger prostates (>30-40 mL). Generally the side effects of 5ARI treatment are mild, and according to the FORTA classification 5ARIs are suitable for frail elderly. 5ARI/alpha-blocker (AB) combination therapy showed the best symptomatic outcome and risk reduction for clinical progression. Combining Phosphodieseterase type 5 inhbibitors (PDE5Is) with 5ARIs counteracts the negative androgenic sexual side effects of 5ARIs, and simultaneously combines their synergistic effects on LUTS.

引用

页码：325 / +

页数：13

共 50 条

[1] 5-ALPHA-REDUCTASE INHIBITORS AND PROSTATIC DISEASE
SCHRODER, FH
[J]. CLINICAL ENDOCRINOLOGY, 1994, 41 (02) : 139 - 147
[2] TREATMENT OF HIRSUTISM WITH 5-ALPHA-REDUCTASE INHIBITORS
BROOKS, JR
[J]. CLINICS IN ENDOCRINOLOGY AND METABOLISM, 1986, 15 (02): : 391 - 405
[3] PROSTATE EFFECTS OF 5-ALPHA-REDUCTASE INHIBITORS
RASMUSSON, GH
REYNOLDS, GF
STEINBERG, NG
PATEL, GF
WALTON, E
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1987, 193 : 8 - MEDI
[4] NOVEL AROMATASE AND 5-ALPHA-REDUCTASE INHIBITORS
DISALLE, E
BRIATICO, G
GIUDICI, D
ORNATI, G
ZACCHEO, T
BUZZETTI, F
NESI, M
PANZERI, A
[J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1994, 49 (4-6): : 289 - 294
[5] 5-Alpha-reductase inhibitors in diseases of the prostate
Carrasquillo, Robert J.
Nealy, Sean W.
Wang, David S.
[J]. CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2014, 21 (06) : 488 - 492
[6] Contraindicated use of 5-alpha-reductase inhibitors in women
Teichert, Martina
van Puijenbroek, Eugene
Stricker, Bruno H.
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (02) : 429 - 431
[7] 5-alpha-reductase inhibitors for prostate cancer prevention
不详
[J]. INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (06) : 553 - 553
[8] The role of 5-alpha-reductase inhibitors in active surveillance
Margel, David
Fleshner, Neil
[J]. CURRENT OPINION IN UROLOGY, 2012, 22 (03) : 243 - 246
[9] AZASTEROIDS AS INHIBITORS OF RAT PROSTATIC 5-ALPHA-REDUCTASE
RASMUSSON, GH
REYNOLDS, GF
UTNE, T
JOBSON, RB
PRIMKA, RL
BERMAN, C
BROOKS, JR
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (12) : 1690 - 1701
[10] STEROIDAL AND NONSTEROIDAL INHIBITORS OF STEROID 5-ALPHA-REDUCTASE
ABELL, AD
HENDERSON, BR
[J]. CURRENT MEDICINAL CHEMISTRY, 1995, 2 (01) : 583 - 597

← 1 2 3 4 5 →